KEYNOTE-091 and IMPOWER010: adjuvant chemotherapy for NSCLC

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLCПодробнее

Differences in treating lung cancer with adjuvant and neoadjuvant immunotherapyПодробнее

IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy in resected NSCLCПодробнее

Immunotherapy as combination and neoadjuvant therapies in NSCLCПодробнее

Keynote 091: Adjuvant Pembrolizumab - OncTalk Lung 2023Подробнее

IMpower010 supports adjuvant atezolizumab in early-stage NSCLC | Heather WakeleeПодробнее

IMpower010: adjuvant atezolizumab improves DFS in resected stage II-IIIA NSCLCПодробнее

IMpower010: OS results of atezolizumab vs best supportive care in resected NSCLCПодробнее

Disease-free survival in IMpower010 trial: adjuvant atezolizumab in NSCLCПодробнее

JAVELIN Lung100, PRIMUS, NintNivo, IMpower010: investigating IO in NSCLCПодробнее

IMPower 010: Adjuvant Atezolizumab in NSCLC - OncTalk Lung 2023Подробнее

Dr Bhuvan | IMpower010 Adjuvant Atezolizumab after adjuvant chemotherapy in resected stage IB IIIAПодробнее

Adjuvant and neoadjuvant chemo-IO for UK patients with NSCLCПодробнее

ASCO 2021 Lung Recap: IMpower010: Atezolizumab after Chemo in Non-Small Cell Lung CancerПодробнее

Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091Подробнее

S1 Episode 4: Managing Lung Cancer With Neoadjuvant and Adjuvant TherapyПодробнее

Subgroup analysis of PEARLS/KEYNOTE-091: PD-L1 expression and outcomes of pembrolizumabПодробнее

What Did We Learn From IMpower010 in Resectable NSCLC? - Medpage TodayПодробнее

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy ...Подробнее